EX-99.1 2 d332478dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

McKESSON REPORTS FISCAL 2017 THIRD-QUARTER RESULTS

 

    Revenues of $50.1 billion for the third quarter, up 5% year-over-year.

 

    Third-quarter GAAP earnings per diluted share from continuing operations of $2.86, up 6% year-over-year.

 

    Excluding Cost Alignment Plan charges of two cents from Adjusted Earnings, third-quarter results per diluted share of $3.05, down 4% compared to $3.18 in the prior year.

 

    Fiscal 2017 Outlook: GAAP earnings per diluted share from continuing operations of $9.80 to $10.30.

 

    Fiscal 2017 Outlook: $12.60 to $12.90 per diluted share, which excludes approximately $1.28 to $1.30 in charges to Adjusted Earnings related to a goodwill impairment and the Cost Alignment Plan, up from previous outlook of $12.35 to $12.85.

 

    Announced definitive agreement to acquire CoverMyMeds to strengthen our technology offerings to pharmaceutical manufacturers, clinicians and payers.

SAN FRANCISCO, January 25, 2017 – McKesson Corporation (NYSE:MCK) today reported that revenues for the third quarter ended December 31, 2016, were $50.1 billion, up 5% compared to $47.9 billion a year ago. On the basis of U.S. generally accepted accounting principles (“GAAP”), third-quarter earnings per diluted share from continuing operations was $2.86, compared to $2.71 a year ago.

Third-quarter Adjusted Earnings were $3.03 per diluted share. Third-quarter results included pre-tax charges totaling $4 million, or approximately two cents per diluted share, related to the company’s cost alignment plan disclosed in March 2016 (the “Cost Alignment Plan”). Third-quarter results primarily benefited from a lower tax rate, partially offset by a softer pricing environment in our U.S. Pharmaceutical business within Distribution Solutions compared to the prior year.

For the first nine months of the fiscal year, McKesson generated cash from operations of $3.3 billion, and ended the quarter with cash and cash equivalents of $2.4 billion. Through the first nine months of the fiscal year, McKesson paid $4.2 billion for acquisitions, repurchased $2.0 billion of its common stock, repaid approximately $390 million in long-term debt, invested

 

1


$369 million internally and paid $192 million in dividends. And our expectation for full-year cash flow from operations remains consistent with our original guidance.

On January 24, 2017, McKesson entered into an agreement to acquire CoverMyMeds for approximately $1.1 billion, or $0.9 billion net of incremental cash tax benefits. The agreement also includes a maximum $0.3 billion of consideration contingent upon CoverMyMeds’ financial performance through the fiscal year ending 2019. CoverMyMeds is a privately-owned company headquartered in Columbus, Ohio, that provides electronic prior authorization solutions to pharmacies, providers, payers and pharmaceutical manufacturers. The transaction is subject to customary closing conditions, including regulatory review, and is expected to close in the first half of Fiscal 2018.

“I am pleased with our strong cash flow generation and our ability to deploy capital in meaningful and productive ways, particularly strategic acquisitions and share repurchases,” said John H. Hammergren, chairman and chief executive officer. “Our announced acquisition of CoverMyMeds supports McKesson’s commitment to provide a comprehensive set of services and solutions that drive value across the healthcare continuum and secure patients’ access to their prescribed drugs. McKesson continues to further enhance its diverse suite of pharmaceutical technology solutions to support the very best in patient care.”

Segment Results

Distribution Solutions revenues were $49.4 billion for the quarter, up 5% on a reported basis and 6% on a constant currency basis.

North America pharmaceutical distribution and services revenues of $41.7 billion for the quarter were up 5% both on a reported and constant currency basis, primarily reflecting market growth and acquisitions, partially offset by branded to generic conversions.

International pharmaceutical distribution and services revenues were $6.2 billion for the quarter, up 3% on a reported basis and 10% on a constant currency basis, driven by acquisitions and market growth.

 

2


Medical-Surgical distribution and services revenues were $1.6 billion for the quarter, down 1% compared to the prior year both on a reported and constant currency basis.

In the third quarter, Distribution Solutions GAAP operating profit was $813 million and GAAP operating margin was 1.64%. On a constant currency basis, third-quarter adjusted operating profit was $809 million, down 24% from the prior year, and adjusted operating margin was 1.62%.

Technology Solutions revenues of $0.7 billion were flat both on a reported and constant currency basis in the third quarter, primarily driven by an anticipated year-over-year decline in our hospital software business, offset by growth in our other technology businesses.

Technology Solutions GAAP operating profit was $132 million for the third quarter and GAAP operating margin was 19.02%. On a constant currency basis, adjusted operating profit was $168 million for the third quarter, up 26% from the prior year, and adjusted operating margin was 24.24%.

“Although we were unfavorably impacted in the third quarter by weaker branded pharmaceutical pricing than anticipated, we are updating our Fiscal 2017 outlook to reflect McKesson’s lower full-year effective tax rate,” continued Hammergren. “As a result, we now expect Adjusted Earnings per diluted share from continuing operations of $12.60 to $12.90 for the fiscal year ending March 31, 2017,” concluded Hammergren.

Fiscal 2017 Outlook

McKesson expects GAAP earnings per diluted share between $9.80 to $10.30 for the fiscal year ending March 31, 2017. Adjusted Earnings per diluted share excludes the following items:

 

    Amortization of acquisition-related intangible assets of $1.30 to $1.45 per diluted share;

 

    Acquisition expenses and related adjustments of 65 cents to 75 cents per diluted share;

 

    LIFO inventory-related credits of 60 to 70 cents per diluted share; and

 

3


    Claim and litigation reserve credits of one cent per diluted share for average wholesale price litigation matters.

Excluding the second-quarter EIS goodwill impairment charge and an anticipated 2 to 4 cents in expected Cost Alignment Plan charges from Adjusted Earnings, McKesson expects $12.60 to $12.90 per diluted share for the fiscal year ending March 31, 2017.

The Fiscal 2017 guidance ranges do not include any potential claim or litigation reserve adjustments, or the impact of any potential new acquisitions and divestitures, or impairments and material restructurings beyond those previously publicly disclosed.

Adjusted Earnings

McKesson separately reports financial results on the basis of Adjusted Earnings. Adjusted Earnings is a non-GAAP financial measure defined as GAAP income from continuing operations, excluding amortization of acquisition-related intangible assets, acquisition expenses and related adjustments, claim and litigation reserve adjustments reflecting the company’s reserves for controlled substance distribution claims and average wholesale price litigation matters, and Last-In-First-Out (“LIFO”) inventory-related adjustments. A reconciliation of McKesson’s GAAP financial results to Adjusted Earnings is provided in Schedules 2, 3 and 4 of the financial statement tables included with this release.

Constant Currency

McKesson also presents its financial results on a constant currency basis. The company conducts business worldwide in local currencies, including the Euro, British pound and Canadian dollar. As a result, the comparability of the financial results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. Constant currency information is presented to provide a framework for assessing how the company’s business performed excluding the effect of foreign currency exchange rate fluctuations. The supplemental constant

 

4


currency information of the company’s GAAP financial results and Adjusted Earnings (Non-GAAP) is provided in Schedule 3 of the financial statement tables included with this release.

Risk Factors

Except for historical information contained in this press release, matters discussed may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These statements may be identified by their use of forward-looking terminology such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “plans”, “estimates” or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. It is not possible to predict or identify all such risks and uncertainties; however, the most significant of these risks and uncertainties are described in the company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: changes in the U.S. healthcare industry and regulatory environment; managing foreign expansion, including the related operating, economic, political and regulatory risks; changes in the Canadian healthcare industry and regulatory environment; exposure to European economic conditions, including recent austerity measures taken by certain European governments; changes in the European regulatory environment with respect to privacy and data protection regulations; fluctuations in foreign currency exchange rates; the company’s ability to successfully identify, consummate, finance and integrate acquisitions; the company’s ability to manage and complete divestitures; material adverse resolution of pending legal proceedings; competition and industry consolidation; substantial defaults in payment or a material reduction in purchases by, or the loss of, a large customer or group purchasing organization; the loss of government contracts as a result of compliance or funding challenges; public health issues in the U.S. or abroad;

 

5


cyberattack, natural disaster, or malfunction of sophisticated internal computer systems to perform as designed; the adequacy of insurance to cover property loss or liability claims; the company’s failure to attract and retain customers for its software products and solutions due to integration and implementation challenges, or due to an inability to keep pace with technological advances; the company’s proprietary products and services may not be adequately protected, and its products and solutions may be found to infringe on the rights of others; system errors or failure of our technology products or services to conform to specifications; disaster or other event causing interruption of customer access to data residing in our service centers; the delay or extension of our sales or implementation cycles for external software products; changes in circumstances that could impair our goodwill or intangible assets; new or revised tax legislation or challenges to our tax positions; general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the company, its customers or suppliers; changes in accounting principles generally accepted in the United States of America; withdrawal from participation in multiemployer pension plans or if such plans are reported to have underfunded liabilities; inability to realize the expected benefits from the company’s restructuring and business process initiatives; difficulties with outsourcing and similar third party relationships; risks associated with the company’s retail expansion; and the company’s inability to keep existing retail store locations or open new retail locations in desirable places. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

Conference Call Details

The company has scheduled a conference call for today, Wednesday, January 25th, at 5:00 PM ET. The dial-in number for individuals wishing to participate on the call is 719-234-7317. Craig Mercer, senior vice president,

 

6


Investor Relations, is the leader of the call, and the password to join the call is ‘McKesson’. The live webcast and supplementary slide presentation for the conference call can be accessed on the company’s Investor Relations website at http://investor.mckesson.com.

A telephonic replay of this conference call will be available for five calendar days. The dial-in number for individuals wishing to listen to the replay is 719-457-0820 and the pass code is 2152494.

The audio webcast and supplemental slide presentation will be archived on the company’s Investor Relations website after the conclusion of the call. Shareholders are encouraged to review the company’s filings with the Securities and Exchange Commission and the supplementary slide presentation for the conference call, which are located on the company’s website.

About McKesson Corporation

McKesson Corporation, currently ranked 5th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. McKesson partners with payers, hospitals, physician offices, pharmacies, pharmaceutical companies, and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit www.mckesson.com.

###

Contact:

Craig Mercer, 415-983-8391 (Investors and Financial Media)

Craig.Mercer@McKesson.com

Kristin Hunter, 415-983-8974 (General and Business Media)

Kristin.Hunter@McKesson.com

 

7


Schedule 1

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP

(unaudited)

(in millions, except per share amounts)

 

     Quarter Ended
December 31,
          Nine Months Ended
December 31,
       
     2016     2015     Change     2016     2015     Change  

Revenues

   $ 50,130      $ 47,899        5   $ 149,820      $ 144,206        4

Cost of sales (1)

     (47,318     (45,027     5        (141,345     (135,642     4   
  

 

 

   

 

 

     

 

 

   

 

 

   

Gross profit

     2,812        2,872        (2     8,475        8,564        (1

Operating expenses (2) (3)

     (1,981     (1,952     1        (5,802     (5,759     1   

Goodwill impairment charge (4)

     —          —          —          (290     —          —     
  

 

 

   

 

 

     

 

 

   

 

 

   

Total operating expenses

     (1,981     (1,952     1        (6,092     (5,759     6   
  

 

 

   

 

 

     

 

 

   

 

 

   

Operating income

     831        920        (10     2,383        2,805        (15

Other income, net

     23        13        77        65        43        51   

Interest expense

     (74     (87     (15     (231     (267     (13
  

 

 

   

 

 

     

 

 

   

 

 

   

Income from continuing operations before income taxes

     780        846        (8     2,217        2,581        (14

Income tax expense (5)

     (131     (204     (36     (570     (704     (19
  

 

 

   

 

 

     

 

 

   

 

 

   

Income from continuing operations after tax

     649        642        1        1,647        1,877        (12

Income (loss) from discontinued operations, net of tax (6)

     (3     5        (160     (117     (11     964   
  

 

 

   

 

 

     

 

 

   

 

 

   

Net income

     646        647        —          1,530        1,866        (18

Net income attributable to noncontrolling interests

     (13     (13     —          (48     (39     23   
  

 

 

   

 

 

     

 

 

   

 

 

   

Net income attributable to McKesson Corporation

   $ 633      $ 634        —     $ 1,482      $ 1,827        (19 )% 
  

 

 

   

 

 

     

 

 

   

 

 

   

Earnings (loss) per common share attributable to McKesson Corporation (7)

            

Diluted

            

Continuing operations

   $ 2.86      $ 2.71        6   $ 7.07      $ 7.86        (10 )% 

Discontinued operations

     (0.01     0.02        (150     (0.51     (0.05     920   
  

 

 

   

 

 

     

 

 

   

 

 

   

Total

   $ 2.85      $ 2.73        4   $ 6.56      $ 7.81        (16 )% 
  

 

 

   

 

 

     

 

 

   

 

 

   

Basic

            

Continuing operations

   $ 2.89      $ 2.74        5   $ 7.14      $ 7.95        (10 )% 

Discontinued operations

     (0.02     0.02        (200     (0.52     (0.04     1,200   
  

 

 

   

 

 

     

 

 

   

 

 

   

Total

   $ 2.87      $ 2.76        4   $ 6.62      $ 7.91        (16 )% 
  

 

 

   

 

 

     

 

 

   

 

 

   

Dividends declared per common share

   $ 0.28      $ 0.28        $ 0.84      $ 0.80     
  

 

 

   

 

 

     

 

 

   

 

 

   

Weighted average common shares

            

Diluted

     222        232        (4 )%      226        234        (3 )% 

Basic

     221        230        (4     224        231        (3

 

(1)  The third quarters of fiscal year 2017 and 2016 include pre-tax credits of $155 million and pre-tax charges of $33 million and the first nine months of fiscal year 2017 and 2016 include pre-tax credits of $151 million and pre-tax charges of $215 million related to our last-in-first-out (“LIFO”) method of accounting for inventories within our Distribution Solutions segment. The first nine months of fiscal year 2017 include $142 million and the third quarter and first nine months of fiscal year 2016 include $17 million and $76 million of net cash proceeds representing our share of antitrust legal settlements.
(2)  The first nine months of fiscal year 2016 include a pre-tax gain of $52 million ($29 million after-tax) recognized from the 2016 second quarter sale of our ZEE Medical business within our Distribution Solutions segment.
(3)  The first nine months of fiscal year 2016 include a pre-tax gain of $51 million ($38 million after-tax) recognized from the 2016 first quarter sale of our nurse triage business within our Technology Solutions segment.
(4)  The first nine months of fiscal year 2017 include a non-cash pre-tax charge of $290 million ($282 million after-tax) recorded to impair the carrying value of goodwill related to our Enterprise Information Solutions (“EIS”) business, which is a reporting unit within our Technology Solutions segment.
(5)  The first nine months of fiscal year 2017 include a tax benefit of $47 million related to the amended accounting guidance on share-based compensation adopted in the first quarter of fiscal year 2017. The third quarter and first nine months of fiscal year 2016 include a $19 million tax benefit related to enacted tax law changes in foreign jurisdictions. The first nine months of fiscal year 2016 also include a $25 million tax benefit related to the reversal of a tax reserve.
(6)  The first nine months of fiscal year 2017 include an after-tax loss of $113 million recognized from the 2017 first quarter sale of our Brazilian pharmaceutical distribution business within our discontinued operations.
(7)  Certain computations may reflect rounding adjustments.


Schedule 2A

McKESSON CORPORATION

RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions, except per share amounts)

 

     Quarter Ended December 31, 2016     Change
Vs. Prior Quarter
 
     As
Reported
(GAAP)
    Amortization
of
Acquisition-
Related
Intangibles
    Acquisition
Expenses
and Related
Adjustments
    Claim and
Litigation
Reserve
Adjustments
    LIFO-Related
Adjustments
    Adjusted
Earnings
(Non-GAAP)
    As
Reported
(GAAP)
    Adjusted
Earnings
(Non-GAAP)
 

Gross profit

   $ 2,812      $ —        $ —        $ —        $ (155   $ 2,657        (2 )%      (9 )% 

Operating expenses

   $ (1,981   $ 102      $ 72      $ —        $ —        $ (1,807     1     (1 )% 

Other income, net

   $ 23      $ —        $ 3      $ —        $ —        $ 26        77     86

Income from continuing operations before income taxes

   $ 780      $ 102      $ 75      $ —        $ (155   $ 802        (8 )%      (21 )% 

Income tax expense

   $ (131   $ (31   $ (14   $ —        $ 61      $ (115     (36 )%      (55 )% 

Income from continuing operations, net of tax, attributable to McKesson Corporation

   $ 636      $ 71      $ 61      $ —        $ (94   $ 674        1     (9 )% 

Diluted earnings per common share from continuing operations, net of tax, attributable to McKesson Corporation (1)

   $ 2.86      $ 0.32      $ 0.27      $ —        $ (0.42   $ 3.03 (2)      6     (5 )% 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

Diluted weighted average common shares

     222        222        222        —          222        222        (4 )%      (4 )% 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     
     Quarter Ended December 31, 2015              
     As
Reported
(GAAP)
    Amortization
of
Acquisition-
Related
Intangibles
    Acquisition
Expenses
and Related
Adjustments
    Claim and
Litigation
Reserve
Adjustments
    LIFO-Related
Adjustments
    Adjusted
Earnings
(Non-GAAP)
             

Gross profit (3)

   $ 2,872      $ 1      $ —        $ —        $ 33      $ 2,906       

Operating expenses

   $ (1,952   $ 107      $ 22      $ —        $ —        $ (1,823    

Other income, net

   $ 13      $ —        $ 1      $ —        $ —        $ 14       

Income from continuing operations before income taxes

   $ 846      $ 108      $ 23      $ —        $ 33      $ 1,010       

Income tax expense (4)

   $ (204   $ (33   $ (8   $ —        $ (13   $ (258    

Income from continuing operations, net of tax, attributable to McKesson Corporation

   $ 629      $ 75      $ 15      $ —        $ 20      $ 739       

Diluted earnings per common share from continuing operations, net of tax, attributable to McKesson Corporation (1)

   $ 2.71      $ 0.32      $ 0.07      $ —        $ 0.08      $ 3.18       
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

Diluted weighted average common shares

     232        232        232        —          232        232       
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

(1)  Certain computations may reflect rounding adjustments.
(2)  Adjusted Earnings per share on a Constant Currency basis for the third quarter of fiscal year 2017 was $3.07 per diluted share, which excludes the foreign currency exchange effect of $0.04 per diluted share.
(3)  Fiscal year 2016 reflects $17 million of net cash proceeds representing our share of antitrust legal settlements within our Distributions Solutions Segment.
(4)  Fiscal year 2016 includes a $19 million tax benefit related to enacted tax law changes in foreign jurisdictions.

For more information relating to the Adjusted Earnings (Non-GAAP) and Constant Currency (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.


Schedule 2B

McKESSON CORPORATION

RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions, except per share amounts)

 

     Nine Months Ended December 31, 2016     Change
Vs. Prior Period
 
     As
Reported
(GAAP)
    Amortization
of
Acquisition-
Related
Intangibles
    Acquisition
Expenses
and Related
Adjustments
    Claim and
Litigation
Reserve
Adjustments
    LIFO-Related
Adjustments
    Adjusted
Earnings
(Non-GAAP)
    As
Reported
(GAAP)
    Adjusted
Earnings
(Non-GAAP)
 

Gross profit (1)

   $ 8,475      $ 3      $ 1      $ —        $ (151   $ 8,328        (1 )%      (5 )% 

Operating expenses (2)

   $ (6,092   $ 328      $ 157      $ (6   $ —        $ (5,613     6     5

Other income, net

   $ 65      $ 1      $ 8      $ —        $ —        $ 74        51     61

Income from continuing operations before income taxes

   $ 2,217      $ 332      $ 166      $ (6   $ (151   $ 2,558        (14 )%      (20 )% 

Income tax expense (3)

   $ (570   $ (100   $ (37   $ 2      $ 59      $ (646     (19 )%      (30 )% 

Income from continuing operations, net of tax, attributable to McKesson Corporation

   $ 1,599      $ 232      $ 129      $ (4   $ (92   $ 1,864        (13 )%      (17 )% 

Diluted earnings per common share from continuing operations, net of tax, attributable to McKesson Corporation (4)

   $ 7.07      $ 1.02      $ 0.57      $ (0.02   $ (0.40   $ 8.24 (5)      (10 )%      (14 )% 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

Diluted weighted average common shares

     226        226        226        226        226        226        (3 )%      (3 )% 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     
     Nine Months Ended December 31, 2015              
     As
Reported
(GAAP)
    Amortization
of
Acquisition-
Related
Intangibles
    Acquisition
Expenses
and Related
Adjustments
    Claim and
Litigation
Reserve
Adjustments
    LIFO-Related
Adjustments
    Adjusted
Earnings
(Non-GAAP)
             

Gross profit (1)

   $ 8,564      $ 5      $ —        $ —        $ 215      $ 8,784       

Operating expenses (6) (7)

   $ (5,759   $ 323      $ 84      $ —        $ —        $ (5,352    

Other income, net

   $ 43      $ 1      $ 2      $ —        $ —        $ 46       

Income from continuing operations before income taxes

   $ 2,581      $ 329      $ 86      $ —        $ 215      $ 3,211       

Income tax expense (8)

   $ (704   $ (103   $ (29   $ —        $ (84   $ (920    

Income from continuing operations, net of tax, attributable to McKesson Corporation

   $ 1,838      $ 226      $ 57      $ —        $ 131      $ 2,252       

Diluted earnings per common share from continuing operations, net of tax, attributable to McKesson Corporation (4)

   $ 7.86      $ 0.96      $ 0.25      $ —        $ 0.56      $ 9.63       
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

Diluted weighted average common shares

     234        234        234        —          234        234       
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

     

 

(1)  Fiscal year 2017 and 2016 include $142 million and $76 million of net cash proceeds representing our share of antitrust legal settlements within our Distribution Solutions segment.
(2)  Fiscal year 2017 includes a non-cash pre-tax charge of $290 million ($282 million after-tax) recorded to impair the carrying value of goodwill related to our EIS business within our Technology Solutions segment.
(3)  Fiscal year 2017 includes a tax benefit of $47 million related to the amended accounting guidance on share-based compensation adopted in the first quarter of fiscal year 2017.
(4)  Certain computations may reflect rounding adjustments.
(5)  Adjusted Earnings per share on a Constant Currency basis for fiscal year 2017 was $8.32 per diluted share, which excludes the foreign currency exchange effect of $0.08 per diluted share.
(6)  Fiscal year 2016 includes a pre-tax gain of $52 million ($29 million after-tax) recognized from the 2016 second quarter sale of our ZEE Medical business within our Distribution Solutions segment.
(7)  Fiscal year 2016 includes a pre-tax gain of $51 million ($38 million after-tax) recognized from the 2016 first quarter sale of our nurse triage business within our Technology Solutions segment.
(8)  Fiscal year 2016 includes a $19 million tax benefit related to enacted tax law changes in foreign jurisdictions and a $25 million tax benefit related to the reversal of a tax reserve.

For more information relating to the Adjusted Earnings (Non-GAAP) and Constant Currency (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.


Schedule 3A

McKESSON CORPORATION

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions)

 

    Quarter Ended December 31, 2016     Quarter Ended December 31, 2015     GAAP     Non-GAAP     Change  
    As
  Reported  
(GAAP)
    Adjustments     Adjusted
  Earnings  
(Non-
GAAP)
    As
  Reported  
(GAAP)
    Adjustments     Adjusted
  Earnings  
(Non-
GAAP)
    Foreign
Currency
Effects
    Constant
Currency
    Foreign
Currency
Effects
    Constant
Currency
    As
Reported
(GAAP)
    Adjusted
Earnings
(Non-
GAAP)
    Constant
Currency
(GAAP)
    Constant
Currency
(Non-
GAAP)
 

REVENUES

                           

Distribution Solutions

                           

North America pharmaceutical distribution & services

  $ 41,685      $ —        $ 41,685      $ 39,615      $ —        $ 39,615      $ 1      $ 41,686      $ 1      $ 41,686        5     5     5     5

International pharmaceutical distribution & services

    6,193        —          6,193        6,022        —          6,022        441        6,634        441        6,634        3        3        10        10   

Medical-Surgical distribution & services

    1,558        —          1,558        1,568        —          1,568        —          1,558        —          1,558        (1     (1     (1     (1

Total Distribution Solutions

    49,436        —          49,436        47,205        —          47,205        442        49,878        442        49,878        5        5        6        6   

Technology Solutions - Products and Services

    694        —          694        694        —          694        (1     693        (1     693        —          —          —          —     

Revenues

  $ 50,130      $ —        $ 50,130      $ 47,899      $ —        $ 47,899      $ 441      $ 50,571      $ 441      $ 50,571        5     5     6     6

GROSS PROFIT

                           

Distribution Solutions (1)

  $ 2,424      $ (155   $ 2,269      $ 2,511      $ 32      $ 2,543      $ 69      $ 2,493      $ 69      $ 2,338        (3 )%      (11 )%      (1 )%      (8 )% 

Technology Solutions

    388        —          388        361        2        363        1        389        1        389        7        7        8        7   

Gross profit

  $ 2,812      $ (155   $ 2,657      $ 2,872      $ 34      $ 2,906      $ 70      $ 2,882      $ 70      $ 2,727        (2 )%      (9 )%      -     (6 )% 

OPERATING EXPENSES

                           

Distribution Solutions

  $ (1,628   $ 140      $ (1,488   $ (1,613   $ 119      $ (1,494   $ (68   $ (1,696   $ (62   $ (1,550     1     —       5     4

Technology Solutions

    (256     35        (221     (240     9        (231     (1     (257     —          (221     7        (4     7        (4

Corporate

    (97     (1     (98     (99     1        (98     1        (96     —          (98     (2     —          (3     —     

Operating expenses

  $ (1,981   $ 174      $ (1,807   $ (1,952   $ 129      $ (1,823   $ (68   $ (2,049   $ (62   $ (1,869     1     (1 )%      5     3

OTHER INCOME, NET

                           

Distribution Solutions

  $ 17      $ 3      $ 20      $ 8      $ 1      $ 9      $ 1      $ 18      $ 1      $ 21        113     122     125     133

Technology Solutions

    —          —          —          1        —          1        —          —          —          —          (100     (100     (100     (100

Corporate

    6        —          6        4        —          4        —          6        —          6        50        50        50        50   

Other income, net

  $ 23      $ 3      $ 26      $ 13      $ 1      $ 14      $ 1      $ 24      $ 1      $ 27        77     86     85     93

OPERATING PROFIT

                           

Distribution Solutions (1)

  $ 813      $ (12   $ 801      $ 906      $ 152      $ 1,058      $ 2      $ 815      $ 8      $ 809        (10 )%      (24 )%      (10 )%      (24 )% 

Technology Solutions

    132        35        167        122        11        133        —          132        1        168        8        26        8        26   

Operating profit

    945        23        968        1,028        163        1,191        2        947        9        977        (8     (19     (8     (18

Corporate

    (91     (1     (92     (95     1        (94     1        (90     —          (92     (4     (2     (5     (2

Income from continuing operations before interest expense and income taxes

  $ 854      $ 22      $ 876      $ 933      $ 164      $ 1,097      $ 3      $ 857      $ 9      $ 885        (8 )%      (20 )%      (8 )%      (19 )% 

STATISTICS

                           

Operating profit as a % of revenues

                           

Distribution Solutions

    1.64       1.62     1.92       2.24       1.63       1.62     (28 ) bp      (62 )bp      (29 )bp      (62 )bp 

Technology Solutions

    19.02          24.06        17.58          19.16          19.05          24.24        144        490        147        508   

 

(1)  Fiscal year 2016 includes $17 million of net cash proceeds representing our share of antitrust legal settlements.

For more information relating to the Adjusted Earnings (Non-GAAP) and Constant Currency (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.


Schedule 3B

McKESSON CORPORATION

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

(unaudited)

(in millions)

 

    Nine Months Ended December 31, 2016     Nine Months Ended December 31, 2015     GAAP     Non-GAAP     Change  
    As
  Reported  
(GAAP)
    Adjustments     Adjusted
  Earnings  
(Non-
GAAP)
    As
  Reported  
(GAAP)
    Adjustments     Adjusted
  Earnings  
(Non-
GAAP)
    Foreign
Currency
Effects
    Constant
Currency
    Foreign
Currency
Effects
    Constant
Currency
    As
Reported
(GAAP)
    Adjusted
Earnings
(Non-
GAAP)
    Constant
Currency
(GAAP)
    Constant
Currency
(Non-
GAAP)
 

REVENUES

                           

Distribution Solutions

                           

North America pharmaceutical distribution & services

  $ 124,271      $ —        $ 124,271      $ 119,750      $ —        $ 119,750      $ 106      $ 124,377      $ 106      $ 124,377        4     4     4     4

International pharmaceutical distribution & services

    18,794        —          18,794        17,726        —          17,726        781        19,575        781        19,575        6        6        10        10   

Medical-Surgical distribution & services

    4,657        —          4,657        4,579        —          4,579        —          4,657        —          4,657        2        2        2        2   

Total Distribution Solutions

    147,722        —          147,722        142,055        —          142,055        887        148,609        887        148,609        4        4        5        5   

Technology Solutions - Products and Services

    2,098        —          2,098        2,151        —          2,151        —          2,098        —          2,098        (2     (2     (2     (2

Revenues

  $ 149,820      $ —        $ 149,820      $ 144,206      $ —        $ 144,206      $ 887      $ 150,707      $ 887      $ 150,707        4     4     5     5

GROSS PROFIT

                           

Distribution Solutions (1)

  $ 7,333      $ (150   $ 7,183      $ 7,462      $ 215      $ 7,677      $ 149      $ 7,482      $ 149      $ 7,332        (2 )%      (6 )%      —       (4 )% 

Technology Solutions

    1,142        3        1,145        1,102        5        1,107        —          1,142        —          1,145        4        3        4        3   

Gross profit

  $ 8,475      $ (147   $ 8,328      $ 8,564      $ 220      $ 8,784      $ 149      $ 8,624      $ 149      $ 8,477        (1 )%      (5 )%      1     (3 )% 

OPERATING EXPENSES

                           

Distribution Solutions (2)

  $ (4,784   $ 399      $ (4,385   $ (4,750   $ 379      $ (4,371   $ (144   $ (4,928   $ (129   $ (4,514     1     —       4     3

Technology Solutions (3) (4)

    (1,017     76        (941     (678     26        (652     (1     (1,018     (1     (942     50        44        50        44   

Corporate

    (291     4        (287     (331     2        (329     1        (290     —          (287     (12     (13     (12     (13

Operating expenses

  $ (6,092   $ 479      $ (5,613   $ (5,759   $ 407      $ (5,352   $ (144   $ (6,236   $ (130   $ (5,743     6     5     8     7

OTHER INCOME, NET

                           

Distribution Solutions

  $ 43      $ 9      $ 52      $ 30      $ 3      $ 33      $ 1      $ 44      $ 1      $ 53        43     58     47     61

Technology Solutions

    1        —          1        2        —          2        —          1        —          1        (50     (50     (50     (50

Corporate

    21        —          21        11        —          11        —          21        —          21        91        91        91        91   

Other income, net

  $ 65      $ 9      $ 74      $ 43      $ 3      $ 46      $ 1      $ 66      $ 1      $ 75        51     61     53     63

OPERATING PROFIT

                           

Distribution Solutions (1) (2)

  $ 2,592      $ 258      $ 2,850      $ 2,742      $ 597      $ 3,339      $ 6      $ 2,598      $ 21      $ 2,871        (5 )%      (15 )%      (5 )%      (14 )% 

Technology Solutions (3) (4)

    126        79        205        426        31        457        (1     125        (1     204        (70     (55     (71     (55

Operating profit

    2,718        337        3,055        3,168        628        3,796        5        2,723        20        3,075        (14     (20     (14     (19

Corporate

    (270     4        (266     (320     2        (318     1        (269     —          (266     (16     (16     (16     (16

Income from continuing operations before interest expense and income taxes

  $ 2,448      $ 341      $ 2,789      $ 2,848      $ 630      $ 3,478      $ 6      $ 2,454      $ 20      $ 2,809        (14 )%      (20 )%      (14 )%      (19 )% 

STATISTICS

                           

Operating profit as a % of revenues

                           

Distribution Solutions

    1.75       1.93     1.93       2.35       1.75       1.93     (18 )bp      (42 )bp      (18 )bp      (42 )bp 

Technology Solutions

    6.01          9.77        19.80          21.25          5.96          9.72        (1,379     (1,148     (1,384     (1,153

 

(1) Fiscal year 2017 and 2016 include $142 million and $76 million of net cash proceeds representing our share of antitrust legal settlements.
(2) Fiscal year 2016 includes a pre-tax gain of $52 million ($29 million after-tax) recognized from the fiscal year 2016 second quarter sale of our ZEE Medical business.
(3) Fiscal year 2017 includes a non-cash pre-tax charge of $290 million ($282 million after-tax) recorded to impair the carrying value of goodwill related to our EIS business.
(4) Fiscal year 2016 includes a pre-tax gain of $51 million ($38 million after-tax) recognized from the fiscal year 2016 first quarter sale of our nurse triage business.

For more information relating to the Adjusted Earnings (Non-GAAP) and Constant Currency (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.


Schedule 4A

McKESSON CORPORATION

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) - BY ADJUSTMENT TYPE

(unaudited)

(in millions)

 

    Quarter Ended December 31, 2016     Quarter Ended December 31, 2015  
    Distribution
Solutions
    Technology
Solutions
    Corporate          Total          Distribution
Solutions
    Technology
Solutions
    Corporate          Total       

As Reported (GAAP):

               

Revenues

  $ 49,436      $ 694      $ —        $ 50,130      $ 47,205      $ 694      $ —        $ 47,899   

Income from continuing operations before interest expense and income taxes (1)

  $ 813      $ 132      $ (91   $ 854      $ 906      $ 122      $ (95   $ 933   

Pre-Tax Adjustments:

               

Amortization of acquisition-related intangibles

  $ 100      $ 2      $ —        $ 102      $ 97      $ 11      $ —        $ 108   

Acquisition expenses and related adjustments

    43        33        (1     75        22        —          1        23   

Claim and litigation reserve adjustments

    —          —          —          —          —          —          —          —     

LIFO-related adjustments

    (155     —          —          (155     33        —          —          33   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total pre-tax adjustments

  $ (12   $ 35      $ (1   $ 22      $ 152      $ 11      $ 1      $ 164   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted Earnings (Non-GAAP):

               

Revenues

  $ 49,436      $ 694      $ —        $ 50,130      $ 47,205      $ 694      $ —        $ 47,899   

Income from continuing operations before interest expense and income taxes (1)

  $ 801      $ 167      $ (92   $ 876      $ 1,058      $ 133      $ (94   $ 1,097   

 

(1)  Fiscal year 2016 reflects $17 million of net cash proceeds representing our share of antitrust legal settlements within our Distribution Solutions segment.

For more information relating to the Adjusted Earnings (Non-GAAP) definition, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.


Schedule 4B

McKESSON CORPORATION

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) - BY ADJUSTMENT TYPE

(unaudited)

(in millions)

 

    Nine Months Ended December 31, 2016     Nine Months Ended December 31, 2015  
    Distribution
Solutions
    Technology
Solutions
    Corporate          Total          Distribution
Solutions
    Technology
Solutions
    Corporate          Total       

As Reported (GAAP):

               

Revenues

  $ 147,722      $ 2,098      $ —        $ 149,820      $ 142,055      $ 2,151      $ —        $ 144,206   

Income from continuing operations before interest
expense and income taxes (1)(2)(3)(4)

  $ 2,592      $ 126      $ (270   $ 2,448      $ 2,742      $ 426      $ (320   $ 2,848   

Pre-Tax Adjustments:

               

Amortization of acquisition-related intangibles

  $ 311      $ 21      $ —        $ 332      $ 298      $ 31      $ —        $ 329   

Acquisition expenses and related adjustments

    104        58        4        166        84        —          2        86   

Claim and litigation reserve adjustments

    (6     —          —          (6     —          —          —          —     

LIFO-related adjustments

    (151     —          —          (151     215        —          —          215   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total pre-tax adjustments

  $ 258      $ 79      $ 4      $ 341      $ 597      $ 31      $ 2      $ 630   
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted Earnings (Non-GAAP):

               

Revenues

  $ 147,722      $ 2,098      $ —        $ 149,820      $ 142,055      $ 2,151      $ —        $ 144,206   

Income from continuing operations before interest
expense and income taxes (1)(2)(3)(4)

  $ 2,850      $ 205      $ (266   $ 2,789      $ 3,339      $ 457      $ (318   $ 3,478   

 

(1) Fiscal year 2017 and 2016 include $142 million and $76 million of net cash proceeds representing our share of antitrust legal settlements within our Distribution Solutions segment.
(2) Fiscal year 2017 includes a non-cash pre-tax charge of $290 million ($282 million after-tax) recorded to impair the carrying value of goodwill related to our EIS business within our Technology Solutions segment.
(3) Fiscal year 2016 includes a pre-tax gain of $52 million ($29 million after-tax) recognized from the fiscal year 2016 second quarter sale of our ZEE Medical business within our Distribution Solutions segment.
(4) Fiscal year 2016 includes a pre-tax gain of $51 million ($38 million after-tax) recognized from the fiscal year 2016 first quarter sale of our nurse triage business within our Technology Solutions segment.

For more information relating to the Adjusted Earnings (Non-GAAP) definition, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.


Schedule 5

McKESSON CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in millions)

 

     December 31,      March 31,  
               2016                          2016            

ASSETS

     

Current Assets

     

Cash and cash equivalents

   $ 2,434       $ 4,048   

Receivables, net

     18,198         17,980   

Inventories, net

     16,121         15,335   

Prepaid expenses and other

     513         437   

Current assets held for sale

     2,002         635   
  

 

 

    

 

 

 

Total Current Assets

     39,268         38,435   

Property, Plant and Equipment, Net

     2,411         2,278   

Goodwill

     10,612         9,786   

Intangible Assets, Net

     3,583         3,021   

Other Noncurrent Assets

     2,000         3,003   
  

 

 

    

 

 

 

Total Assets

   $ 57,874       $ 56,523   
  

 

 

    

 

 

 

LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY

     

Current Liabilities

     

Drafts and accounts payable

   $ 30,811       $ 28,585   

Short-term borrowings

     1,406         7   

Deferred revenue

     402         919   

Current portion of long-term debt

     1,748         1,610   

Other accrued liabilities

     3,113         3,288   

Current liabilities held for sale

     694         660   
  

 

 

    

 

 

 

Total Current Liabilities

     38,174         35,069   

Long-Term Debt

     5,969         6,497   

Long-Term Deferred Tax Liabilities

     2,884         2,734   

Other Noncurrent Liabilities

     1,684         1,809   

Redeemable Noncontrolling Interests

     1,311         1,406   

McKesson Corporation Stockholders’ Equity

     7,692         8,924   

Noncontrolling Interests

     160         84   
  

 

 

    

 

 

 

Total Equity

     7,852         9,008   
  

 

 

    

 

 

 

Total Liabilities, Redeemable Noncontrolling Interests and Equity

   $ 57,874       $ 56,523   
  

 

 

    

 

 

 


Schedule 6

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in millions)

 

     Nine Months Ended December 31,  
     2016     2015  

OPERATING ACTIVITIES

    

Net income

   $ 1,530      $ 1,866   

Adjustments to reconcile to net cash provided by operating activities:

    

Depreciation and amortization

     663        671   

Goodwill impairment

     290        —     

Other deferred taxes

     122        30   

Share-based compensation expense

     109        113   

LIFO charges (credits)

     (151     215   

Loss (gain) from sales of businesses

     113        (103

Other non-cash items

     50        139   

Changes in operating assets and liabilities, net of acquisitions:

    

Receivables

     (654     (1,667

Inventories

     (374     (2,397

Drafts and accounts payable

     1,891        1,695   

Deferred revenue

     (58     (66

Taxes

     52        114   

Other

     (274     (44
  

 

 

   

 

 

 

Net cash provided by operating activities

     3,309        566   
  

 

 

   

 

 

 

INVESTING ACTIVITIES

    

Property acquisitions

     (246     (272

Capitalized software expenditures

     (123     (145

Acquisitions, net of cash and cash equivalents acquired

     (4,174     (25

Proceeds from/(payment for) sale of businesses, net

     (91     204   

Restricted cash for acquisitions

     935        —     

Other

     80        10   
  

 

 

   

 

 

 

Net cash used in investing activities

     (3,619     (228
  

 

 

   

 

 

 

FINANCING ACTIVITIES

    

Proceeds from short-term borrowings

     2,803        1,532   

Repayments of short-term borrowings

     (1,405     (1,668

Repayments of long-term debt

     (392     (996

Common stock transactions:

    

Issuances

     89        97   

Share repurchases, including shares surrendered for tax withholding

     (2,060     (960

Dividends paid

     (192     (179

Other

     12        (73
  

 

 

   

 

 

 

Net cash used in financing activities

     (1,145     (2,247
  

 

 

   

 

 

 

Effect of exchange rate changes on cash and cash equivalents

     (159     (26
  

 

 

   

 

 

 

Net decrease in cash and cash equivalents

     (1,614     (1,935

Cash and cash equivalents at beginning of period

     4,048        5,341   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 2,434      $ 3,406   
  

 

 

   

 

 

 


SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION

In an effort to provide investors with additional information regarding the company’s financial results as determined by generally accepted accounting principles (“GAAP”), McKesson Corporation (the “Company” or “we”) also presents the following non-GAAP measures in this press release. The Company believes the presentation of non-GAAP measures provides useful supplemental information to investors with regard to its operating performance, as well as assists with the comparison of its past financial performance to the Company’s future financial results. Moreover, the Company believes that the presentation of non-GAAP measures assists investors’ ability to compare its financial results to those of other companies in the same industry. However, the Company’s non-GAAP measures used in the press tables may be defined and calculated differently by other companies in the same industry.

 

    Adjusted Earnings (Non-GAAP): We define Adjusted Earnings as GAAP income from continuing operations, excluding amortization of acquisition-related intangible assets, acquisition expenses and related adjustments, certain claim and litigation reserve adjustments and Last-In-First-Out (“LIFO”) inventory-related adjustments, as well as the related income tax effects. The Company evaluates its definition of Adjusted Earnings on a periodic basis and updates the definition from time to time. The evaluation considers both the quantitative and qualitative aspect of the Company’s presentation of Adjusted Earnings. A reconciliation of McKesson’s GAAP financial results to Adjusted Earnings (Non-GAAP) is provided in Schedules 2, 3 and 4 of the financial statement tables included with this release.

Amortization of acquisition-related intangibles - Amortization expense of acquired intangible assets purchased in connection with business acquisitions by the Company.

Acquisition expenses and related adjustments - Transaction and integration expenses that are directly related to business acquisitions and the proposed Healthcare Technology Net Asset Exchange by the Company. Examples include transaction closing costs, professional service fees, restructuring or severance charges, retention payments, employee relocation expenses, facility or other exit-related expenses, recoveries of acquisition-related expenses or post-closing expenses, bridge loan fees, gains or losses related to foreign currency contracts, and gains or losses on business combinations.

Claim and litigation reserve adjustments - Adjustments to the Company’s reserves, including accrued interest, for estimated probable losses for its Controlled Substance Distribution Claims and the Average Wholesale Price litigation matters, as such terms are defined in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2016.

LIFO-related adjustments - Last-In-First-Out (“LIFO”) inventory-related adjustments.

Income taxes on Adjusted Earnings are calculated in accordance with Accounting Standards Codification (“ASC”) 740, “Income Taxes,” which is the same accounting principle used by the Company when presenting its GAAP financial results.

 

    Constant Currency (Non-GAAP): To present our financial results on a constant currency basis, we convert current year period results of our operations in foreign countries, which are recorded in local currencies, into U.S. dollars by applying the average foreign currency exchange rates of the comparable prior year period. To present Adjusted Earnings per diluted share on a constant currency basis, we estimate the impact of foreign currency rate fluctuations on the Company’s noncontrolling interests and adjusted income tax expense, which may vary from quarter to quarter. The supplemental constant currency information of the Company’s GAAP financial results and Adjusted Earnings (Non-GAAP) is provided in Schedule 3 of the financial statement tables included with this release.

The Company internally uses non-GAAP financial measures in connection with its own financial planning and reporting processes. Specifically, Adjusted Earnings serves as one of the measures management utilizes when allocating resources, deploying capital and assessing business performance and employee incentive compensation. The Company conducts its business worldwide in local currencies, including Euro, British pound and Canadian dollar. As a result, the comparability of our results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. We present constant currency information to provide a framework for assessing how our business performed excluding the estimated effect of foreign currency exchange rate fluctuations. Nonetheless, non-GAAP financial results and related measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.